Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
$0.01
$0.00
$3.46
$16K-2.3951,674 shsN/A
Avitar, Inc. stock logo
AVTI
Avitar
$0.00
$0.00
$0.00
N/A-0.29N/AN/A
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
$0.16
$0.03
$2.90
$1.25M-0.81N/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.28
+8.5%
$1.28
$0.35
$2.11
$329.38M3.518.05 million shs5.38 million shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
0.00%0.00%0.00%0.00%+7,380.00%
Avitar, Inc. stock logo
AVTI
Avitar
0.00%0.00%0.00%0.00%0.00%
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
0.00%0.00%0.00%0.00%-71.43%
Ocugen, Inc. stock logo
OCGN
Ocugen
0.00%-10.61%-31.79%+118.07%+63.89%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
N/AN/AN/AN/AN/AN/AN/AN/A
Avitar, Inc. stock logo
AVTI
Avitar
N/AN/AN/AN/AN/AN/AN/AN/A
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
N/AN/AN/AN/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
0.8128 of 5 stars
3.51.00.00.02.30.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
N/AN/AN/AN/A
Avitar, Inc. stock logo
AVTI
Avitar
N/AN/AN/AN/A
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
N/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
3.00
Buy$4.67264.58% Upside

Current Analyst Ratings

Latest OCGN, BNKL, AVTI, and AHPI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
4/3/2024
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
2/22/2024
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
$27.05M0.00N/AN/A$1.30 per share0.00
Avitar, Inc. stock logo
AVTI
Avitar
N/AN/AN/AN/AN/AN/A
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
$1.80M0.00N/AN/A($0.24) per share0.00
Ocugen, Inc. stock logo
OCGN
Ocugen
$6.04M54.53N/AN/A$0.16 per share8.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
-$5.36M-$1.34N/AN/AN/AN/AN/AN/AN/A
Avitar, Inc. stock logo
AVTI
Avitar
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
-$4.95M-$0.710.00N/AN/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
-$63.08M-$0.27N/AN/AN/AN/A-102.97%-77.75%5/3/2024 (Estimated)

Latest OCGN, BNKL, AVTI, and AHPI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
Ocugen, Inc. stock logo
OCGN
Ocugen
N/A-$0.04-$0.04-$0.04N/A$6.04 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
N/AN/AN/AN/AN/A
Avitar, Inc. stock logo
AVTI
Avitar
N/AN/AN/AN/AN/A
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
N/AN/AN/A
Avitar, Inc. stock logo
AVTI
Avitar
N/AN/AN/A
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
N/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
0.07
2.51
2.51

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
4.15%
Avitar, Inc. stock logo
AVTI
Avitar
N/A
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
N/A
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%

Insider Ownership

CompanyInsider Ownership
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
5.10%
Avitar, Inc. stock logo
AVTI
Avitar
7.40%
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
34.71%
Ocugen, Inc. stock logo
OCGN
Ocugen
3.48%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
1894.01 million3.81 millionNot Optionable
Avitar, Inc. stock logo
AVTI
Avitar
36N/AN/ANot Optionable
Bionik Laboratories Corp. stock logo
BNKL
Bionik Laboratories
1212.48 million8.15 millionNot Optionable
Ocugen, Inc. stock logo
OCGN
Ocugen
84257.33 million248.37 millionOptionable

OCGN, BNKL, AVTI, and AHPI Headlines

SourceHeadline
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGNROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
prnewswire.com - April 26 at 6:34 PM
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc.OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc.
bakersfield.com - April 26 at 3:11 PM
Ocugen (OCGN) to Report Q1 Earnings: Whats in the Cards?Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - April 26 at 3:11 PM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 26 at 1:30 PM
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
markets.businessinsider.com - April 26 at 10:02 AM
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingUPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
globenewswire.com - April 26 at 9:05 AM
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingOcugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
globenewswire.com - April 26 at 6:30 AM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 25 at 1:30 PM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 24 at 6:45 PM
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmIMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
prnewswire.com - April 23 at 11:30 AM
Ocugen (NASDAQ:OCGN) Price Target Increased to $5.00 by Analysts at Chardan CapitalOcugen (NASDAQ:OCGN) Price Target Increased to $5.00 by Analysts at Chardan Capital
americanbankingnews.com - April 23 at 3:32 AM
Ocugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan CapitalOcugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan Capital
marketbeat.com - April 22 at 8:29 AM
Key Takeaways From Ocugen Analyst RatingsKey Takeaways From Ocugen Analyst Ratings
markets.businessinsider.com - April 22 at 8:19 AM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 22 at 7:00 AM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
markets.businessinsider.com - April 21 at 10:14 AM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 21 at 7:00 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGNSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
prnewswire.com - April 20 at 11:00 AM
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive ValueOcugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
seekingalpha.com - April 19 at 8:04 PM
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
prnewswire.com - April 19 at 12:00 PM
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene TherapyOcugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
globenewswire.com - April 19 at 7:13 AM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 19 at 7:00 AM
Ocugen stock jumps after $175M securities filingOcugen stock jumps after $175M securities filing
msn.com - April 18 at 9:05 AM
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 18 at 9:00 AM
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsOcugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
stockhouse.com - April 18 at 12:44 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Allied Healthcare Products logo

Allied Healthcare Products

NASDAQ:AHPI
Allied Healthcare Products, Inc. engages in manufacturing respiratory products used in the health care industry in hospitals and alternate site settings, including sub-acute care facilities, home health care and emergency medical care. Its product line includes respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.
Avitar logo

Avitar

OTCMKTS:AVTI
Avitar, Inc. is a holding company which through its subsidiaries designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine such as crack; marijuana; and methamphetamines, including meth and ecstasy. The company also provides foam disposable products including medical-grade hydrophilic polyurethane foam disposables such as wound dressings comprising Hydrasorb, a wound dressing product for exudating wounds; and various custom foam products comprising a sinus dressing and a device used by astronauts for relieving ear pressure while in a pressurized space suit. In addition, it develops specialty wound dressings for the cardiac catheter lab market, as well as the Illizarov Dressing used for dressing external bone fixators in orthopedic procedures. The company markets its products and services to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations through direct sales force and strategic partners, as well as through a network of distributors. Avitar, Inc. was founded in 1986 and is based in Canton, Massachusetts with Additional office in Calgary, Canada.
Bionik Laboratories logo

Bionik Laboratories

OTCMKTS:BNKL
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.
Ocugen logo

Ocugen

NASDAQ:OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.